Newsletter

Jetzt noch besser informiert!

Abonnieren auch Sie unseren kostenlosen Nachrichten-Newsletter und verpassen Sie nichts mehr aus der wallstreet:online Redaktion!

  • Das Wichtigste für Sie zusammengefasst
  • Ausgewählte Artikel unserer Gastautoren
  • Eilmeldungen zu wichtigen Marktgeschehnissen

Wir respektieren Ihre Privatsphäre, es werden keine Daten an Dritte weitergegeben!

Jetzt abonnieren
Später
Push-Kurse an | Registrieren | Login
DAX+0,02 % EUR/USD-0,35 % Gold-1,07 % Öl (Brent)-0,86 %

EQS-Adhoc LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service

Nachrichtenquelle: EQS Group AG
09.02.2016, 07:00  |  330   |   |   
EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Regulatory Approval
LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service

09.02.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

LifeWatch(TM) receives FDA clearance for its continuous Vital Signs
Monitoring Service

Zug/Switzerland, February 9, 2016 - LifeWatch AG (SIX Swiss Exchange:
LIFE), a leading developer and provider of medical solutions and remote
diagnostic monitoring services in the digital health market, is pleased to
announce that it has received FDA clearance for its continuous Vital Signs
Monitoring Service.

The wireless, patch-based vital signs monitoring system makes vital signs
monitoring faster, easier and more convenient for both, patients and
medical staff. It will allow for early detection of vital sign changes
thereby enabling faster interventions as well as increased nursing
efficiency and higher patient satisfaction.

The Vital Signs Patch is an easy-to-use cable-free sensor worn on a
patient's upper chest. It is intended to be used on adult patients in a
clinical environment for the continuous, non-invasive monitoring of ECG,
heart rate, respiration rate, surface temperature, arterial blood oxygen
saturation and body position. It will be available in two versions (with
and without ECG) and is connected with an easy-to-use wireless supporting
system, which provides medical information and alerts remotely to medical
staff. Although the system will initially be used in a medical facility
(hospital, nursing home, etc.), the even larger ambulatory market should
follow once the technology has been proven in the clinical environment.

Dr. Stephan Rietiker, CEO of LifeWatch, stated: "This clearance represents
another significant technological breakthrough for LifeWatch and further
strengthens our position as an innovational leader in digital health. I am
highly excited at the tremendous market potential for the easy-to-use Vital
Signs Patch, both in the clinical and ambulatory settings worldwide.
Furthermore, the cost benefits will allow vital signs monitoring to be
utilized for a much broader patient population. However, providing service
in a clinical environment is a new market for LifeWatch and will therefore
require both time and additional resources in order to ensure a successful
market launch."


For further questions:

LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser
Phone: +41 43 268 32 35 / +41 79 410 81 88
E-mail: investor-relations@lifewatch.com


About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),

Switzerland, is a leading healthcare technology and solution company,
specializing in advanced digital health systems and wireless remote
diagnostic patient monitoring services. LifeWatch's services provide
physicians with critical information to determine appropriate treatment and
thereby improve patient outcomes. LifeWatch AG has operative subsidiaries
in the United States, in Switzerland and in Israel, and is the parent
company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd.
LifeWatch Services, Inc. is a leading U.S.-based provider of cardiac
monitoring services and home sleep testing of Obstructive Sleep Apnea
(OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer
and manufacturer of telemedicine products. For additional information,
please visit www.lifewatch.com.

Sign up for customized e-mail alerts and documentation requests at
http://www.irlifewatch.com/alert-service.aspx

This press release includes forward-looking statements. All statements
other than statements of historical facts contained in this press release,
including statements regarding future results of operations and financial
position, the business strategy, and plans and objectives for future
operations, are forward-looking statements. The words "believe," "may,"
"will," "estimate," "continue," "anticipate," "intend," "expect" and
similar expressions are intended to identify forward-looking statements.
LifeWatch AG has based these forward-looking statements largely on current
expectations and projections about future events and financial trends that
it believes may affect the financial condition, results of operations,
business strategy, short-term and long-term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light of
these risks, uncertainties and assumptions, the forward-looking events and
circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only
on data available to LifeWatch AG at the time of the issue of this press
release. LifeWatch AG does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of
new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL
CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN
OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN
THE UNITED STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED
STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES
SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED
STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM
LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

End of ad hoc announcement

+++++
Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=SOCCCRLJKY
Document title: LifeWatch(TM) receives FDA clearance for its continuous
Vital Signs Monitoring Service

---------------------------------------------------------------------------

09.02.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------------


Language: English
Company: LifeWatch AG
Baarerstrasse 139
6300 Zug
Switzerland
Phone: +41 41 728 67 78
Internet: www.lifewatch.com
ISIN: CH0012815459
Valor: 811189
Listed: Regulated Unofficial Market in Berlin, Stuttgart; Open
Market in Frankfurt ; SIX


End of News EQS Group News Service
---------------------------------------------------------------------------

435611 09.02.2016

Wertpapier: LifeWatch

Themen: SEC, UBS, IFE


Schreibe Deinen Kommentar

 

Disclaimer

EQS-Adhoc LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service

EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Regulatory Approval LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service 09.02.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible …

Die Daten werden nur zum Versenden der Nachricht benutzt und nicht gespeichert.

Abbrechen

Weitere Nachrichten des Autors

Titel
Titel
Titel
Titel